Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436282 | 1.00 | SLC6A9 (0.53) | SLC6A9C5AR1DRD2DRD4SIRT1 | |
| SCHEMBL3434276 | 0.86 | SLC6A9 (0.53) | SLC6A9C5AR1DRD2DRD4SIRT1 | |
| SCHEMBL3435656 | 0.86 | SLC6A9 (0.53) | SLC6A9C5AR1DRD2DRD4SIRT1 | |
| SCHEMBL3436233 | 0.82 | SLC6A9 (0.49) | SLC6A9C5AR1SIRT1SIRT2ALDH1A1 | |
| SCHEMBL3434159 | 0.82 | SLC6A9 (0.49) | SLC6A9C5AR1SIRT1SIRT2ALDH1A1 | |
| SCHEMBL3551334 | 0.80 | SLC6A9 (0.44) | SLC6A9MAPTALDH1A1 | |
| SCHEMBL3558414 | 0.80 | SLC6A9 (0.44) | SLC6A9MAPTALDH1A1 | |
| SCHEMBL3556320 | 0.78 | SLC6A9 (0.43) | SLC6A9MAPTALDH1A1 | |
| SCHEMBL3436312 | 0.77 | SIRT1 (0.40) | SIRT1SIRT2MAPTTLR8TLR7 | |
| SCHEMBL3436281 | 0.75 | AR (0.44) | SIRT1SIRT2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SLC6A9 3516/4885C5AR1 1309/4885DRD2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.